Android app Apple app link

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

By AP NEWS   |   1 day ago
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson is acquiring Intra-Cellular Therapies for over $14 billion to expand its central nervous system disorder treatments. This deal is expected to close later this year and includes Intra-Cellular's drug Caplyta, with projected sales to exceed $2.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.